Product image of Meriofert Pfs (Luteinising Hormone (Human), Follicle-Stimulating Hormone) supplied by GNH India

Meriofert Pfs

Active Ingredient:
Luteinising Hormone (Human), Follicle-Stimulating Hormone
Origin:
EU

Meriofert Pfs (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

Luteinising Hormone (Human) and Follicle‑Stimulating Hormone, the active ingredients in Meriofert Pfs, are gonadotropins presented as an injectable preparation for intramuscular, subcutaneous use. It stimulates gonadal steroidogenesis and gametogenesis in individuals with reproductive hormone deficiencies.

GNH India supplies Meriofert Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert Pfs contains human luteinising hormone and follicle‑stimulating hormone and is used in reproductive hormone therapy.

  • Ovulation induction: supports follicular development and triggers ovulation in women with anovulation.
  • Controlled ovarian stimulation: enhances follicular response in assisted reproductive technology cycles.
  • Male hypogonadotropic hypogonadism: stimulates spermatogenesis in men with deficient gonadotropins.

How It Works

  • The preparation provides exogenous luteinising hormone and follicle‑stimulating hormone that bind to LH and FSH receptors on ovarian and testicular cells. Activation of these receptors stimulates intracellular cyclic AMP pathways, leading to increased steroid hormone production and the maturation of gametes, thereby restoring normal reproductive function.

Side Effects

Adverse reactions may occur following administration of Meriofert Pfs.

Common Side Effects

  • Injection site pain or erythema: mild local discomfort at the injection site.
  • Headache: transient headache reported in some patients.
  • Abdominal discomfort: mild stomach upset or cramping.
  • Nausea: occasional feeling of nausea after dosing.
  • Mild ovarian hyperstimulation: limited follicular response without severe complications.

Serious or Rare Side Effects

  • Ovarian hyperstimulation syndrome: severe fluid shift and abdominal distension.
  • Multiple pregnancy: increased risk of twins or higher order gestations.
  • Thromboembolic events: rare clot formation requiring immediate attention.
  • Allergic reaction: rash, urticaria, or anaphylaxis.
  • Ectopic pregnancy: rare implantation outside the uterus.
  • Severe abdominal pain: may indicate complications such as ovarian torsion.

Precautions & Warnings

Careful assessment and monitoring are required when using Meriofert Pfs.

  • Pregnancy: avoid unless prescribed by a fertility specialist, as safety data are limited.
  • Breastfeeding: use with caution; potential effects on milk production are unknown.
  • Ovarian response: monitor follicular development to prevent excessive stimulation.
  • Hormone‑dependent tumors: contraindicated in patients with known estrogen‑sensitive neoplasms.
  • Specialist supervision: administration should be overseen by qualified reproductive endocrinologists.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Potential drug interactions should be evaluated before initiating therapy.

Major Interactions (Avoid)

  • Hormonal contraceptives: may antagonize the intended gonadotropin effect.
  • Other gonadotropins: additive stimulation can precipitate severe ovarian hyperstimulation.

Moderate Interactions (Monitor Closely)

  • GnRH agonists or antagonists: may alter the pharmacodynamic response.
  • Corticosteroids: can affect hormone metabolism and response.
  • Anticoagulants: monitor for clotting abnormalities if ovarian hyperstimulation occurs.
  • Thyroid hormone therapy: adjust dosing as thyroid status influences gonadotropin activity.

Frequently Asked Questions

Meriofert Pfs is a combination of human luteinising hormone and follicle‑stimulating hormone used to treat infertility. It supports ovulation induction in women, enhances ovarian response during assisted reproductive technology, and stimulates spermatogenesis in men with gonadotropin deficiencies.

The drug supplies exogenous LH and FSH that bind to their specific receptors on ovarian and testicular cells. This binding activates intracellular signaling pathways that increase steroid hormone production and promote the maturation of oocytes or sperm, thereby restoring normal reproductive function.

The dose of Meriofert Pfs is individualized. A qualified prescriber determines the amount, frequency, and route of administration based on the patient’s clinical condition, response to therapy, and treatment protocol.

Safety in pregnancy has not been established, and the product should only be used under specialist guidance if pregnancy is intended. During breastfeeding, caution is advised because the effect on milk production and the infant is not well defined.

To order, submit an enquiry on the Meriofert Pfs product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Meriofert Pfs combines both LH and FSH in a single injectable formulation, offering a convenient option compared with separate LH and FSH preparations. This dual action can simplify dosing regimens and may improve synchronization of follicular development, but clinical choice depends on individual patient needs and physician preference.

Meriofert Pfs must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use to maintain stability.

The product is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. Administration is performed by a trained healthcare professional following aseptic technique and the dosing schedule prescribed by the treating specialist.

Serious risks include ovarian hyperstimulation syndrome, which can cause severe abdominal pain, fluid accumulation, and thromboembolic complications, as well as the possibility of multiple pregnancy, allergic reactions, and rare ectopic pregnancy. Prompt medical attention is required if any of these events occur.

Meriofert Pfs is contraindicated in patients with known hormone‑dependent tumors, uncontrolled thyroid disease, or severe ovarian cysts. It should also be avoided in individuals with a history of severe allergic reactions to any component of the formulation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Luteinising Hormone (Human), Follicle-Stimulating Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT